Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study-Reference-Cited by-同舟云学术

Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study

Published:2017-06-21 Issue:2 Volume:99 Page:169-177
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Reiser Marcel¹,Borte Michael²,Huscher Dörte³,Baumann Ulrich⁴,Pittrow David⁵^ORCID,Sommer Claudia⁶,Stangel Martin⁷,Fasshauer Maria²,Gold Ralf⁸,Hensel Manfred⁹

Affiliation:

1. PIOH - Praxis internistischer Onkologie und Hämatologie; Köln Germany

2. Paediatric Rheumatology, Immunology and Infectiology; Hospital St. Georg; Leipzig Germany

3. Epidemiology unit; German Rheumatism Research Centre; A Leibniz institute; Berlin Germany

4. Paediatric Pulmonology, Allergy and Neonatology; Hanover Medical School; Hanover Germany

5. Medical Faculty; Institute for Clinical Pharmacology; Technical University Dresden; Dresden Germany

6. Department of Neurology; University Hospital Würzburg; Würzburg Germany

7. Department of Neurology; Hanover Medical School; Hanover Germany

8. Department for Neurology; St. Josef-Hospital; Ruhr University Bochum; Bochum Germany

9. Mannheimer Onkologie Praxis; Mannheim Germany

Funder

Baxter Healthcare Corporation

Baxalta GmbH Germany

Baxalta Healthcare, USA

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12900/fullpdf

Reference37 articles.

1. A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia;Lachance;Curr Oncol,2016

2. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia;Compagno;Front Immunol,2014

3. The immunodeficiency of chronic lymphocytic leukaemia;Hamblin;Br Med Bull,2008

4. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes;Parikh;Cancer,2015

5. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia;Hensel;Br J Haematol,2003

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adequate IVIG dosing is associated with an improved long-term outcome in secondary immunodeficiency: A prospective, non-interventional study;Int. Journal of Clinical Pharmacology and Therapeutics;2024-07-30

2. Variation in immunoglobulin use and impact on survival in myeloma;eJHaem;2024-06-16

3. Access and use of immunoglobulins in supportive cancer care: A thematic analysis of a systematic review data set;The Journal of Medicine Access;2024-01

4. Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives;Leukemia Research;2023-10

5. Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis;Cancers;2023-09-12